NKT2152
Neoplasms, Glandular and Epithelial
NiKang Therapeutics, Inc.Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
24 Active assets in the Neoplasms, Glandular and Epithelial cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sorafenib Shandong Cancer Hospital and Institute | Phase 3 | BB |
Catumaxomab Neovii Biotech | Phase 2/3 | B |
Pembrolizumab Sheba Medical Center | Phase 2 | B |
Enadenotucirev Akamis Bio | Phase 1/2 | B |
Linifanib Abbott | Phase 3 | B |
View all 36 →
Same molecule, other indications
NKT2152 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →